Adaptimmune Therapeutics plc
ADAP
$0.0585
$0.00142.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 87.74% | 126.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 87.74% | 126.10% | |||
| Cost of Revenue | -14.31% | -24.09% | |||
| Gross Profit | 47.43% | 37.55% | |||
| SG&A Expenses | -14.50% | -24.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.39% | -24.18% | |||
| Operating Income | 31.27% | 31.69% | |||
| Income Before Tax | 36.76% | 35.18% | |||
| Income Tax Expenses | 6.43% | -66.04% | |||
| Earnings from Continuing Operations | 36.24% | 35.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.24% | 35.88% | |||
| EBIT | 31.27% | 31.69% | |||
| EBITDA | 33.23% | 32.55% | |||
| EPS Basic | 37.93% | 36.17% | |||
| Normalized Basic EPS | 36.17% | 28.88% | |||
| EPS Diluted | 35.17% | 40.10% | |||
| Normalized Diluted EPS | 36.17% | 28.88% | |||
| Average Basic Shares Outstanding | 2.75% | 0.43% | |||
| Average Diluted Shares Outstanding | 2.75% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||